Johnson & Johnson has announced more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the company’s US manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.
In building this facility, Johnson & Johnson continues to invest in cutting-edge manufacturing processes and in training to develop a workforce skilled in advanced technologies that are shaping the future of medicine. It will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.
The announcement is part of the company’s previously announced $55 billion investment in manufacturing, research and development, and technology through early 2029.
This investment further strengthens the company’s longstanding economic impact across Pennsylvania, which totals approximately $10 billion annually. With ten facilities encompassing more than 2 million square feet dedicated to manufacturing, research, distribution, and office operations, Johnson & Johnson maintains one of the most significant, statewide footprints in the healthcare industry.
